CA1252778A — Steroids
Assigned to F Hoffmann La Roche AG · Expires 1989-04-18 · 37y expired
What this patent protects
Abstract Steroids of the formula I wherein n represents the number 2,3 or 4; R1 represents hydrogen, lower-alkyl or lower-alkylidene: R2, R3 and R4 represent hydrogen or lower-alkyl and the dotted C-C bonds in the 5(6)-, 7(8)-, 22(23)-, 24(28)-and 25(26)-position …
USPTO Abstract
Abstract Steroids of the formula I wherein n represents the number 2,3 or 4; R1 represents hydrogen, lower-alkyl or lower-alkylidene: R2, R3 and R4 represent hydrogen or lower-alkyl and the dotted C-C bonds in the 5(6)-, 7(8)-, 22(23)-, 24(28)-and 25(26)-position are optional, whereby the B-ring can contain only one double bond and the side-chain is either saturated or is mono-unsaturated or is di-unsaturated in the 22(23), 25(26)-position: and whereby R1 is lower-alkyl or lower-alkylidene when a 5(6)-double bond is present, n is Z and R2, R3 and R4 are methyl and pharmaceutically acceptable salts of these steroids have activity inhibiting the intestinal resorption of cholesterol. They can be manufactured from steroids which are otherwise substituted in the 3B-position.
Drugs covered by this patent
- Abilify (aripiprazole) · Generic (originally Otsuka/BMS)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.